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A bs tr ac t
Background
Hepatitis C virus (HCV) infection is the leading indication for liver transplantation 
worldwide, and interferon-containing regimens are associated with low response 
rates owing to treatment-limiting toxic effects in immunosuppressed liver-transplant 
recipients. We evaluated the interferon-free regimen of the NS5A inhibitor ombitas-
vir coformulated with the ritonavir-boosted protease inhibitor ABT-450 (ABT-450/r), 
the nonnucleoside NS5B polymerase inhibitor dasabuvir, and ribavirin in liver-trans-
plant recipients with recurrent HCV genotype 1 infection.
Methods
We enrolled 34 liver-transplant recipients with no fibrosis or mild fibrosis, who 
received ombitasvir–ABT-450/r (at a once-daily dose of 25 mg of ombitasvir, 150 mg 
of ABT-450, and 100 mg of ritonavir), dasabuvir (250 mg twice daily), and ribavirin 
for 24 weeks. Selection of the initial ribavirin dose and subsequent dose modifica-
tions for anemia were at the investigator’s discretion. The primary efficacy end point 
was a sustained virologic response 12 weeks after the end of treatment.
Results
Of the 34 study participants, 33 had a sustained virologic response at post-treat-
ment weeks 12 and 24, for a rate of 97% (95% confidence interval, 85 to 100). The 
most common adverse events were fatigue, headache, and cough. Five patients (15%) 
required erythropoietin; no patient required blood transfusion. One patient discon-
tinued the study drugs owing to adverse events after week 18 but had a sustained 
virologic response. Blood levels of calcineurin inhibitors were monitored, and dos-
ages were modified to maintain therapeutic levels; no episode of graft rejection was 
observed during the study.
Conclusions
Treatment with the multitargeted regimen of ombitasvir–ABT-450/r and dasabuvir 
with ribavirin was associated with a low rate of serious adverse events and a high 
rate of sustained virologic response among liver-transplant recipients with recurrent 
HCV genotype 1 infection, a historically difficult-to-treat population. (Funded by AbbVie; 
CORAL-I ClinicalTrials.gov number, NCT01782495.)
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Hepatitis C virus (HCV) presents a global health care challenge, with ap-proximately 170 million people chroni-
cally infected.1 In 2012, approximately 24,000 
liver transplantations were performed world-
wide, with the largest proportion performed be-
cause of HCV-induced liver disease.2,3 In the 
United States, more than 40% of registrants on 
the liver-transplant waiting list are infected with 
HCV.3,4 After liver transplantation, recurrence of 
HCV infection is universal among recipients with 
viremia before transplantation.5,6 Fibrosis pro-
gression may be accelerated and HCV viral loads 
may be markedly increased in patients receiving 
post-transplantation immunosuppressive therapy 
as compared with patients not undergoing trans-
plantation.7-9 Graft cirrhosis develops in 20 to 
30% of HCV-infected persons within 5 years after 
transplantation.10,11 As a result of these compli-
cations, HCV infection has become the leading 
cause of death in liver-transplant recipients. Pa-
tient and graft survival rates are markedly lower 
among HCV-infected patients than among those 
who received a liver transplant owing to choles-
tatic or alcohol-related liver disease.3,12,13
Successful clearance of HCV after liver trans-
plantation can reduce the risk of subsequent 
HCV-related complications such as progression 
to cirrhosis and graft loss.13-16 The standard of 
care in the treatment of recurrent HCV genotype 1 
infection after liver transplantation has been 48 
weeks of peginterferon with ribavirin, though 
the response rates of 13 to 43% are generally 
lower than the rates of 40 to 52% among pa-
tients not undergoing transplantation, in part 
because of treatment-limiting toxic effects.8,15,17-19 
In addition, interferon-based therapies can induce 
alloimmune graft injury, reducing patient and 
graft survival.16,20
Calcineurin inhibitors, such as tacrolimus 
and cyclosporine, are key components of most 
current post-transplantation immunosuppressive 
regimens. Long-term exposure to calcineurin 
inhibitors can progressively impair renal func-
tion, reducing ribavirin clearance. Consequently, 
augmented ribavirin exposure may increase the 
frequency and severity of ribavirin-associated 
hemolytic anemia, commonly requiring the use 
of hematopoietic growth factors, blood transfu-
sion, or both. HCV treatment with a first-gener-
ation protease inhibitor, boceprevir or telaprevir, 
in combination with peginterferon and ribavirin 
results in a 20 to 71% response rate among liver-
transplant recipients; however, clinically signifi-
cant side effects of these regimens, especially 
anemia and infections, were reported to limit 
their use.21-24 In addition, drug interactions be-
tween protease inhibitors and calcineurin inhibi-
tors may require dose modification and moni-
toring.25,26
Phase 3 trials of an all-oral, interferon-free, 
direct-acting antiviral regimen of ombitasvir 
coformulated as a single tablet with ritonavir-
boosted ABT-450 (ABT-50/r) plus dasabuvir and 
ribavirin have shown high rates of sustained vi-
rologic response among patients with HCV geno-
type 1 infection, irrespective of prior treatment 
with peginterferon–ribavirin or the presence of 
cirrhosis.27-31 Ombitasvir is a potent NS5A in-
hibitor32; ABT-450 is an NS3/4A protease inhibitor 
coadministered with ritonavir to increase peak, 
trough, and overall drug exposure, permitting 
once-daily dosing33; and dasabuvir is a nonnu-
cleoside NS5B polymerase inhibitor. Next-gener-
ation interferon-free treatment regimens have not 
been extensively examined in transplant recipi-
ents with recurrent HCV genotype 1 infection. 
The CORAL-I trial assessed the safety and efficacy 
of ombitasvir–ABT-450/r and dasabuvir with riba-
virin in this population of patients with an un-
met need for safe and efficacious therapy.
Me thods
PATIENTS
Patients 18 to 70 years of age were eligible for the 
study if they had HCV genotype 1 infection (HCV 
RNA level >10,000 IU per milliliter) and had re-
ceived a liver transplant at least 12 months before 
screening because of chronic HCV infection. Pa-
tients could have received interferon-based treat-
ment for HCV infection before transplantation 
but not after transplantation. Eligible patients 
had no evidence of advanced fibrosis (Metavir 
score ≤F2) on liver biopsy performed not more 
than 6 months before screening. A stable tacroli-
mus-based or cyclosporine-based immunosuppres-
sive regimen was required, and glucocorticoids 
were permitted at a dose of no more than 5 mg per 
day. Patients were excluded if they were coinfect-
ed with the human immunodeficiency virus or 
hepatitis B virus or had undergone multiple-organ 
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transplantation or liver retransplantation. Patients 
were enrolled from 10 transplantation centers in 
the United States and Spain between May and 
August 2013. Detailed eligibility criteria are pro-
vided in the Supplementary Appendix, available 
with the full text of this article at NEJM.org.
STUDY DESIGN AND OVERSIGHT
Patients in this phase 2, open-label trial received 
ombitasvir–ABT-450/r (at a once-daily dose of 
25 mg of ombitasvir, 150 mg of ABT-450, and 
100 mg of ritonavir) and dasabuvir (250 mg twice 
daily) for 24 weeks. Ribavirin dosing was at the 
investigator’s discretion because of the known 
risk of ribavirin-related hematologic toxic effects in 
transplant recipients. Patients were followed for 
up to 48 weeks after the treatment period (Fig. S1 
in the Supplementary Appendix).
On the basis of simulations based on phar-
macokinetic data from a phase 1 study that evalu-
ated drug interaction between the study drugs and 
tacrolimus or cyclosporine, the following dosages 
of calcineurin inhibitors were recommended: for 
cyclosporine, one fifth of the pretreatment total 
daily dose, administered once daily; for tacroli-
mus, 0.5 mg once weekly or 0.2 mg, where avail-
able, every 3 days. Modifications in tacrolimus 
or cyclosporine dosing during treatment were 
guided by scheduled testing of trough levels of 
calcineurin inhibitors. Details of the dosing of 
ribavirin and calcineurin inhibitors are provided 
in the Supplementary Appendix.
The study was conducted in accordance with 
International Conference on Harmonisation Guide-
lines for Good Clinical Practice, applicable regu-
lations, and guidelines governing clinical-study 
conduct that have their origin in the Declaration 
of Helsinki. All patients provided written informed 
consent. The study was designed by the sponsor 
(AbbVie); the investigators and the sponsor 
jointly conducted the study and gathered the 
data. The sponsor conducted the data analyses. 
All authors signed a confidentiality agreement 
with the sponsor. The first draft of the manu-
script was written by a sponsor-employed med-
ical writer, with input from all the authors. All 
the authors made the decision to submit the 
manuscript for publication and vouch for the com-
pleteness and accuracy of the data and analyses 
and for the fidelity of the study to the protocol, 
which is available at NEJM.org.
EFFICACY AND SAFETY ASSESSMENTS
The primary efficacy end point was a sustained 
virologic response, defined as a plasma HCV RNA 
level of less than 25 IU per milliliter, 12 weeks 
after the end of treatment. Secondary assess-
ments included the percentage of patients with a 
sustained virologic response at post-treatment 
week 24, virologic failure during treatment, and 
post-treatment relapse. A central laboratory used 
the COBAS TaqMan real-time reverse-transcrip-
tase–polymerase-chain-reaction assay, version 2.0 
(Roche), to test plasma samples for HCV RNA. 
Patients were monitored for clinical and labora-
tory evidence of adverse events at each study visit. 
Nonserious adverse events were recorded during 
the treatment period and until 30 days after the 
last dose. Serious adverse events were recorded 
from the time of informed consent until the end 
of the study. Details of plasma-sample collection, 
HCV RNA quantification, virologic-failure crite-
ria, and resistance testing are provided in the 
Supplementary Appendix.
STATISTICAL ANALYSIS
Analyses of efficacy, safety, and baseline patient 
characteristics were performed on the intention-
to-treat population, defined as all enrolled patients 
who received at least one dose of study drugs. 
The two-sided 95% confidence intervals for re-
sponse rates were calculated with the use of the 
exact method based on the beta distribution. Pa-
tients with missing data at post-treatment week 
12 or 24, including those who dropped out, were 
counted as having had virologic failure. Descrip-
tive statistics are provided, such as the number of 
observations, mean, and standard deviation for 
continuous variables and counts and percentages 
for discrete variables. SAS software for the UNIX 
operating system (SAS Institute) was used for all 
analyses.
R esult s
BASELINE DEMOGRAPHIC AND CLINICAL 
CHARACTERISTICS
The CORAL-I study enrolled 34 patients, includ-
ing 29 patients (85%) with HCV genotype 1a in-
fection. The median time since liver transplanta-
tion was 3.3 years. Overall, 76% of patients had a 
non-CC IL28B genotype, 71% had previously been 
treated with peginterferon–ribavirin therapy, and 
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85% were receiving a tacrolimus-based immuno-
suppressive regimen (Table 1).
TREATMENT EFFICACY
By week 4 of treatment, HCV RNA levels had de-
creased to less than 25 IU per milliliter in all 34 
patients (Table 2); all the patients also had HCV 
RNA levels of less than 25 IU per milliliter at the 
end of treatment. With regard to the primary end 
point, 33 of 34 patients had a sustained virologic 
response at post-treatment week 12, for a rate of 
97% (95% confidence interval [CI], 85 to 100). 
One patient did not have a sustained virologic 
response owing to a relapse on post-treatment 
day 3. No relapses occurred after post-treatment 
week 12; 33 of 34 patients (97%) had a sustained 
virologic response at post-treatment week 24. All 
5 patients infected with genotype 1b (100%) and 
28 of 29 patients infected with genotype 1a (97%) 
had a sustained virologic response. The remaining 
patient had resistance-associated variants R155K 
in NS3, M28T and Q30R in NS5A, and G554S in 
NS5B at the time of relapse, none of which were 
present at baseline. The NS3 variant Q80K was 
present in 11 of 29 patients (38%) with HCV gen-
otype 1a infection at baseline, including the pa-
tient with a relapse, who had had a null response 
to prior peginterferon–ribavirin therapy. Variants 
at resistance-associated positions in NS3, NS5A, 
and NS5B were each observed in at least 1 patient at 
baseline (Table S1 in the Supplementary Appendix).
SAFETY
Adverse events were common, though the major-
ity were mild or moderate in severity (Table 3). 
The most common adverse events were fatigue, 
headache, and cough. None of the patients had 
graft rejection and there were no deaths during 
the study. One patient discontinued the study 
drugs after week 18 owing to rash, memory im-
pairment, and anxiety. These events were as-
sessed as having a reasonable possibility of being 
related to the study drugs; they were moderate in 
severity. This patient had a sustained virologic 
response 12 weeks after ending treatment pre-
maturely. Two patients (6%) had serious adverse 
events. Narratives on these two patients are pro-
vided in the Supplementary Appendix.
Grade 3 laboratory abnormalities were infre-
quent, and no grade 4 abnormalities were ob-
served. Grade 3 elevations in the total bilirubin 
Table 1. Baseline Demographic and Clinical Characteristics of the 34 Study 
Participants.*
Characteristic Value
Male sex — no. (%) 27 (79)




Hispanic or Latino ethnic group — no. (%)† 6 (18)
Age — yr 59.6±6.6
Body-mass index‡ 29.7±4.5
HCV genotype 1a — no. (%) 29 (85)
IL28B non-CC genotype — no. (%)§ 26 (76)
HCV RNA — log10 IU/ml 6.6±0.5
Lack of response to peginterferon–ribavirin treatment 
before transplantation — no. (%)
24 (71)




Time since liver transplantation — mo
Median 39.5
Range 12.9–136.4
Primary immunosuppressive medication — no. (%)
Tacrolimus 29 (85)
Cyclosporine 5 (15)
Other immunosuppressive medication — no. (%)
Mycophenolic acid 11 (32)
Prednisone 2 (6)
Creatinine clearance — ml/min 90.5±26.4
Creatinine — mg/dl‖ 1.1±0.23
Alkaline phosphatase — U/liter 109.3±40.4




* Plus–minus values are means ±SD. HCV denotes hepatitis C virus.
† Race and ethnic group were self-reported.
‡ The body-mass index is the weight in kilograms divided by the square of the 
height in meters.
§ The IL28B genotype was determined from DNA in peripheral blood obtained 
at baseline.
¶ The Metavir fibrosis score (on a scale from F0 to F4, with F0 indicating no fi-
brosis and F4 fibrosis consistent with compensated cirrhosis) was based on a 
liver-biopsy specimen reviewed by a central pathologist.
‖To convert the values for creatinine to micromoles per liter, multiply by 88.4.
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level were observed in two patients (6%), occur-
ring within the first 8 days of treatment in both. 
No patient had jaundice or scleral icterus. Eleva-
tions in the total bilirubin level predominantly 
reflected elevated values for indirect bilirubin, a 
finding consistent with inhibition of the organic 
anion–transporting protein 1B1 by protease in-
hibitors. In one patient, total bilirubin levels 
were transiently elevated on day 92, to a value 
that was more than 2 times the upper limit of 
the normal range (predominantly accounted for 
by an elevated indirect bilirubin level), and ala-
nine aminotransferase levels were transiently 
elevated on day 85, to a value that was more than 
3 times the upper limit of the normal range. The 
values returned to the normal range on day 120 
and on post-treatment day 4, respectively. Owing 
to persistent low-grade elevation of alanine ami-
notransferase levels during treatment, a liver bi-
opsy was performed. The biopsy revealed mark-
edly less necroinflammation than the prestudy 
biopsy, a finding consistent with a resolving 
HCV infection (Fig. S2 in the Supplementary Ap-
pendix). This patient had a sustained virologic 
response at post-treatment week 12.
Grade 2 declines in hemoglobin levels (8 to 
<10 g per deciliter) occurred in nine patients 
(26%). One patient had a grade 3 decline in the 
hemoglobin level (6.5 to <8.0 g per deciliter) on 
day 15 and stopped ribavirin for 10 days. Eryth-
ropoietin was subsequently administered from 
day 26 to day 53; the hemoglobin level normal-
ized by treatment day 42.
RIBAVIRIN DOSING
The initial doses of ribavirin ranged from 400 to 
1200 mg daily (Table 4). The majority of patients 
received 600 or 800 mg daily at study initiation 
(19 of 34 [56%]) and also at the completion of 
treatment (23 of 34 [68%]). Overall, 19 patients 
(56%) had a modification in the ribavirin dose 
during treatment; 9 patients (26%) had modifica-
tions owing to declines in hemoglobin levels. 
Five patients (15%) received erythropoietin after 
detection of a nadir hemoglobin level of 7.6 to 
9.1 g per deciliter. All 5 of these patients had 
initial ribavirin doses of 1000 to 1200 mg daily, 
and all 5 had a sustained virologic response at 
post-treatment week 12. No patient received a 
blood transfusion.
DOSING OF CALCINEURIN INHIBITORS
Modifications in the dose or dosing frequency of 
calcineurin inhibitors were made on the basis of 
blood levels of tacrolimus or cyclosporine. For 
most patients who received tacrolimus, 0.5-mg 
and 0.2-mg doses of tacrolimus were adminis-
tered with a median dosing frequency of 10 days 
and 5 days, respectively. The geometric mean and 
range of trough blood concentrations of tacroli-
mus and cyclosporine during treatment were 
similar to those observed in the pretreatment pe-
riod and were within the desired therapeutic 
range (Fig. S3 in the Supplementary Appendix).
The mean creatinine clearance was 90.5 ml 
per minute at baseline and 85.9 ml per minute at 
week 24. No patient had a creatinine clearance 
of less than 50 ml per minute during treatment. 
Five of 29 patients (17%) had tacrolimus concen-
trations of more than 15.0 ng per milliliter dur-
ing the treatment period, although dosing errors 
accounted for the elevations in 4 of the 5 patients. 
Only one adverse event (mild rash) was reported 
in a patient with an elevated tacrolimus level. 
Shortly after treatment completion, 8 patients 
(28%) had one or more tacrolimus measurements 
below the laboratory reference range; in all the 
patients, levels returned to the therapeutic range 
during subsequent follow-up, and no graft rejec-
Table 2. Response during and after Treatment.
Outcome Patients with Outcome
no. % (95% CI)
HCV RNA <25 IU/ml
During treatment period
At wk 4 34 100 (90–100)
At wk 24 34 100 (90–100)
After end of treatment
At wk 4 33 97 (85–100)
At wk 12 33 97 (85–100)
At wk 24 33 97 (85–100)
Virologic failure during treatment 0 0 (0–10)
Relapse* 1 3 (0–15)
* Virologic relapse was defined as a confirmed HCV RNA level of 25 IU per mil-
liliter or more between the final visit and 12 weeks after the last dose of study 
drugs among patients who had an HCV RNA level of less than 25 IU per milli-
liter at the final visit.
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tion occurred. The suggested adjustments in the 
cyclosporine dose maintained trough concentra-
tions within the therapeutic range.
Neither tacrolimus nor cyclosporine substan-
tially altered the trough concentrations of ombit-
asvir, ABT-450, dasabuvir, or ribavirin. The trough 
concentrations of the study drugs were within 
the range observed in phase 2 and 3 studies of 
this regimen.27-31,34
Discussion
Previous studies have shown that overall graft 
and patient survival rates are lower among liver-
transplant recipients with HCV infection than 
among transplant recipients without HCV infec-
tion, owing to universal reinfection and acceler-
ated disease progression. No existing therapeutic 
regimens are approved for HCV-infected liver-
transplant recipients. In the phase 2 CORAL-I 
trial of a 24-week, interferon-free, all-oral antivi-
ral regimen for HCV genotype 1 infection, a rate 
of sustained virologic response of 97% (95% CI, 
85 to 100) at post-treatment weeks 12 and 24 was 
observed among liver-transplant recipients with 
no fibrosis or mild fibrosis. Sustained virologic 
responses of 96 to 100% have been reported in 
phase 3 studies of 12 weeks of treatment with 
ombitasvir–ABT-450/r and dasabuvir with ribavi-
rin in nonimmunosuppressed patients not un-
dergoing liver transplantation.27-30
Studies of a first-generation protease inhibi-
tor (boceprevir or telaprevir) in combination with 
peginterferon and ribavirin have shown lower 
rates of sustained virologic response (20 to 71%) 
and high rates of toxic effects among immuno-
suppressed patients after transplantation, and 
some of these toxic effects can be life-threaten-
ing.21-24 In a phase 2 evaluation, treatment with 





Any adverse event 33 (97)
Any adverse event leading to discon tinuation of study drugs 1 (3)*










Muscle spasms 7 (21)
Rash 7 (21)
Back pain 6 (18)
Dizziness 6 (18)
Peripheral edema 6 (18)
Rhinorrhea 6 (18)








* One patient discontinued the study drugs owing to moderate rash, memory 
impairment, and anxiety after week 18. This patient had a sustained virologic 
response 12 weeks after ending treatment prematurely.
† A serious adverse event was defined as one that resulted in hospitalization or 
prolongation of hospitalization, persistent or clinically significant disability or 
incapacity, or death or that was life-threatening or required medical or surgi-
cal intervention to prevent a serious outcome.
‡ Common adverse events are those that occurred in more than 15% of pa-
tients during the treatment period.
§ The laboratory abnormalities listed here reflect post-baseline, post-nadir val-
ues. For alanine aminotransferase, aspartate aminotransferase, and alkaline 
phosphatase, a level of grade 3 was defined as a level that was more than  
5 times and no more than 20 times the upper limit of the normal range. A to-
tal bilirubin level of grade 3 was defined as a level that was more than 3 times 
and no more than 10 times the upper limit of the normal range. A hemoglo-
bin level of grade 3 was defined as a level of 6.5 to less than 8.0 g per decili-
ter. An abnormal creatinine clearance rate was defined as a rate of less than 
50 ml per minute. A creatinine level of grade 3 was defined as a level of 2.1 to 
less than 2.5 mg per deciliter (186 to <221 μmol per liter).









400 mg 3 (9) 4 (12)
600 mg 12 (35) 14 (41)
800 mg 7 (21) 9 (26)
1000 mg 4 (12) 5 (15)
1200 mg 8 (24) 2 (6)
The New England Journal of Medicine 
Downloaded from nejm.org on January 29, 2018. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
Antivir al Regimen for HCV after Liver Tr ansplantation
n engl j med 371;25 nejm.org december 18, 2014 2381
the nucleotide polymerase inhibitor sofosbuvir 
and ribavirin for 24 weeks resulted in a sustained 
virologic response at post-treatment week 12 in 
28 of 40 liver-transplant recipients (70%).35 The 
patients included in these studies generally had 
advanced fibrosis, which may be associated with 
a decreased response rate.
Treatment of liver-transplant recipients with 
telaprevir or boceprevir plus peginterferon and 
ribavirin is associated with high rates of treat-
ment discontinuation owing to adverse events. 
Side effects of these regimens result in frequent 
use of erythropoietin (in 77 to 100% of patients), 
modifications in the ribavirin dose (in 70 to 
100%), and blood transfusions (in 33 to 64%) to 
manage anemia.21-24 Grade 3 and grade 4 labora-
tory abnormalities were each observed in 28% of 
patients receiving treatment with sofosbuvir and 
ribavirin, including hemoglobin levels of less 
than 8.0 mg per deciliter in 20% of patients,35 
although this study population included patients 
with cirrhosis, and such abnormalities may be 
observed more frequently in patients with cir-
rhosis than in those without cirrhosis.
In our study, doses of immunosuppressive 
calcineurin inhibitors were modified during the 
treatment period to maintain therapeutic levels. 
No deaths or episodes of graft rejection oc-
curred in this population of difficult-to-cure 
transplant recipients with HCV infection. The 
rates of serious adverse events and study discon-
tinuations due to adverse events observed in this 
small study were lower than the rates that have 
been observed with the interferon-based treat-
ments that were the previous standard of care.36 
Only one patient discontinued the study treat-
ment owing to adverse events, and this patient 
had a sustained virologic response. In this im-
munosuppressed population, no new safety sig-
nals were identified, and events related to impair-
ment of renal function and grade 3 laboratory 
abnormalities were similar to those observed in 
larger trials of this regimen involving patients 
not undergoing transplantation.27-31,34 However, 
this study was not large enough to accurately 
estimate rates of adverse events or to make com-
parisons with rates of adverse events in prior 
trials. No patient needed a blood transfusion; 
five patients (15%) required erythropoietin, all 
of whom had initially received ribavirin at a total 
daily dose of 1000 or 1200 mg. These five patients 
were among the first study participants to receive 
the study drugs, and this observation was com-
municated to the investigators with a suggestion 
to use a lower starting dose of ribavirin. Given the 
high response rate that was observed, regardless 
of the initial ribavirin dose, an initial dose of 
600 to 800 mg may provide sufficient therapeu-
tic benefit and minimize the risk of severe anemia.
This study has limitations. Patients were ex-
cluded if they had advanced fibrosis (Metavir 
score >F2) or had received interferon-based 
treatment after transplantation; thus, the study 
selected patients with cases of HCV infection 
that have historically been easier to treat than 
those characterized by advanced fibrosis. In ad-
dition, patients underwent transplantation at 
least 12 months before study initiation, so the 
study excluded those with early, aggressive forms 
of recurrent HCV infection (e.g., fibrosing chole-
static hepatitis) that can complicate treatment. 
Another limitation of the study was that immu-
nosuppressive agents other than tacrolimus and 
cyclosporine were not evaluated; we assessed 
only these two agents because previous studies 
of interactions between drugs were restricted to 
these two agents.
In light of the worldwide organ shortage, a 
safe and effective antiviral regimen is needed for 
the treatment of HCV-infected liver-transplant 
recipients, who have lower survival rates than 
other liver-transplant recipients. Treatment of re-
current HCV infection after liver transplantation 
is associated with improved outcomes in patients 
who have a sustained virologic response,13-15 in-
cluding improvements in graft and patient sur-
vival, changes that may potentially reduce the 
demand for retransplantation.8 We found that 
the multitargeted regimen of ombitasvir–ABT-450/r 
and dasabuvir with ribavirin resulted in a 97% re-
sponse rate among immunosuppressed liver-trans-
plant recipients with recurrent HCV genotype 1 
infection. This all-oral, interferon-free regimen 
was efficacious in eradicating HCV infection in 
a patient population who are at high risk for 
severe illness and death and for whom treatment 
options are currently limited.
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